Literature DB >> 14720581

IDO and tolerance to tumors.

David H Munn1, Andrew L Mellor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14720581     DOI： 10.1016/j.molmed.2003.11.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


× No keyword cloud information.
  91 in total

1.  Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis.

Authors:  Adriano Boasso; Caroline M Royle; Spyridon Doumazos; Veronica N Aquino; Mara Biasin; Luca Piacentini; Barbara Tavano; Dietmar Fuchs; Francesco Mazzotta; Sergio Lo Caputo; Gene M Shearer; Mario Clerici; David R Graham
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

Review 2.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  Adjuvant immunotherapy of experimental autoimmune encephalomyelitis: immature myeloid cells expressing CXCL10 and CXCL16 attract CXCR3+CXCR6+ and myelin-specific T cells to the draining lymph nodes rather than the central nervous system.

Authors:  Richard A O'Connor; Xujian Li; Seth Blumerman; Stephen M Anderton; Randolph J Noelle; Dyana K Dalton
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

Review 4.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

Review 5.  α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions.

Authors:  Diane C Chugani
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

6.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 7.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.

Authors:  Qizhi Tang; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2008-03       Impact factor: 25.606

8.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

9.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO.

Authors:  Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.